Patients who have been on Wegovy or Zepbound through the program would face three options: Pay out of pocket at retail prices (currently $1,000-$1,300 per month) Discontinue the medication , which research suggests leads to significant weight regain Transition to an alternative covered treatment , such as bariatric surgery or other covered medications The STEP 1 extension study showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year
Early detection & prompt medical attention are crucial to improve outcomes
31.6%, p =0.04), in addition to significant reductions in levels of IL-6, IL-18, TNF-alpha and endotoxins but not levels of arterial ammonia
While the concept is scientifically sound, it's essential to recognize that most peptides being used clinically have not completed rigorous FDA-approval processes , and much of our understanding comes from preclinical (animal) studies or small, uncontrolled human observations
Posted 5/29